Renaissance Technologies LLC Acquires 29,400 Shares of Neurogene Inc. $NGNE

Renaissance Technologies LLC lifted its holdings in shares of Neurogene Inc. (NASDAQ:NGNE) by 210.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,400 shares of the company’s stock after buying an additional 29,400 shares during the period. Renaissance Technologies LLC’s holdings in Neurogene were worth $875,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of NGNE. Balyasny Asset Management L.P. bought a new position in Neurogene in the third quarter valued at approximately $12,114,000. Jennison Associates LLC raised its stake in shares of Neurogene by 35.3% during the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock worth $10,982,000 after purchasing an additional 138,999 shares in the last quarter. State Street Corp raised its stake in shares of Neurogene by 47.8% during the 4th quarter. State Street Corp now owns 307,797 shares of the company’s stock worth $6,341,000 after purchasing an additional 99,487 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Neurogene by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock valued at $5,145,000 after buying an additional 3,262 shares during the last quarter. Finally, Logos Global Management LP acquired a new stake in shares of Neurogene in the 4th quarter valued at approximately $4,017,000. Institutional investors own 52.37% of the company’s stock.

Insider Activity

In other news, CFO Christine Mikail Cvijic sold 4,200 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total value of $151,746.00. Following the transaction, the chief financial officer owned 84,040 shares of the company’s stock, valued at approximately $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 9,600 shares of company stock worth $339,932 in the last three months. Insiders own 11.68% of the company’s stock.

Neurogene News Summary

Here are the key news stories impacting Neurogene this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $65 price target while raising its FY2027 EPS forecast to a loss of $4.99 per share from a projected loss of $5.92. The firm also lifted its estimates for the first three quarters of 2027, indicating expectations for reduced losses over time.
• Positive Sentiment: HC Wainwright increased its Q4 2026 EPS estimate to a loss of $1.20 from $1.37 and raised its Q1–Q4 2027 estimates to losses of $1.22, $1.24, $1.26 and $1.27, respectively. These revisions suggest improving operating expectations beyond 2026.
• Positive Sentiment: Canaccord Genuity lowered its price target to $166, but the revised target remains substantially above Neurogene’s recent trading level, potentially reinforcing the stock’s significant upside narrative. Canaccord Genuity Group Lowers Neurogene Price Target
• Neutral Sentiment: HC Wainwright lowered its FY2026 EPS estimate modestly to a loss of $5.44 from $5.39 and trimmed its Q3 2026 estimate to a loss of $1.36 from $1.34. Neurogene is still expected to remain unprofitable, with consensus full-year EPS at a loss of $5.63.
• Negative Sentiment: The company’s latest quarterly results missed analyst expectations, reporting a $1.53-per-share loss versus the $1.42 consensus estimate. Continued losses and the absence of current earnings make the stock highly dependent on clinical and development progress.

Neurogene Price Performance

NASDAQ:NGNE opened at $36.14 on Friday. The company has a market cap of $723.20 million, a P/E ratio of -7.18 and a beta of 1.70. The firm’s fifty day moving average price is $34.11 and its two-hundred day moving average price is $26.90. Neurogene Inc. has a one year low of $15.93 and a one year high of $43.66.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Tuesday, August 11th. The company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11). As a group, equities research analysts expect that Neurogene Inc. will post -5.62 earnings per share for the current year.

Analyst Ratings Changes

NGNE has been the topic of a number of recent analyst reports. HC Wainwright lowered their target price on shares of Neurogene from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Wednesday. Guggenheim lifted their price objective on shares of Neurogene from $69.00 to $81.00 and gave the company a “buy” rating in a research report on Wednesday. Rodman & Renshaw began coverage on shares of Neurogene in a research note on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Friday, July 17th. Finally, UBS Group set a $70.00 price target on Neurogene in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Neurogene Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.